Table 2 HSP expression in TETs and ITMIG recommended outcome measures.
ITMIG recommended outcome measures | HSP expression in TETs | |||||
|---|---|---|---|---|---|---|
Cytoplasmic HSP27 | Cytoplasmic HSP70 | Nuclear HSP70 | ||||
Overall Survival (OS) | weak (n = 5) | mod/str (n = 90) | weak (n = 15) | mod/str (n = 80) | weak (n = 10) | mod/str (n = 85) |
1 year | 100% | 100% | 100% | 100% | 100% | 100% |
5 year | 100% | 96.3% | 93.3% | 97.2% | 100% | 96.1% |
10 year | 66.7% | 92% | 81.7% | 92.4% | 87.5% | 91.4% |
p-value a | 0.867 | 0.377 | 0.980 | |||
Cancer Specific Survival (CSS) | weak | mod/str | weak | mod/str | weak | mod/str |
1 year | 100% | 100% | 100% | 100% | 100% | 100% |
5 year | 100% | 97.7% | 93.3% | 98.7% | 100% | 97.6% |
10 year | 66.7% | 95.6% | 81.7% | 96.4% | 87.5% | 95.3% |
p-value a | 0.352 | 0.291 | 0.985 | |||
Freedom From Recurrence (FFR) | weak | mod/str | weak | mod/str | weak | mod/str |
1 year | 100% | 100% | 100% | 100% | 100% | 100% |
5 year | 60% | 95.3% | 72% | 97.1% | 60% | 97.5% |
10 year | 60% | 92% | 72% | 93.3% | 60% | 93.9% |
p-value a | 0.017 | 0.082 | 0.016 | |||
